Global vaccine industry:
Key developments (July 2025)

Western vaccine manufacturers Pfizer-BioNTech: Expanded RSV vaccine recommendations for older adults The Centers for Disease Control and Prevention (CDC) updated its guidance to recommend the Pfizer-BioNTech RSV vaccine for adults aged 50 years and older with comorbidities. This decision is based on recent phase 3 trial data demonstrating a significant reduction in RSV-associated lower respiratory tract disease and hospitalizations in this population. The expanded indication aims to mitigate the high morbidity and mortality burden of RSV in older adults, particularly those with chronic cardiopulmonary conditions. This update may influence immunization strategies globally, given the aging population and increasing RSV disease burden.1 Moderna: Full FDA approval for pediatric COVID-19 vaccine in high-risk children Moderna’s mRNA COVID-19 vaccine (Spikevax) received full FDA licensure for children aged 6 months to 11 years with underlying medical conditions that increase risk for severe COVID-19. This represents a pivotal regulatory milestone, transitioning from emergency use authorization to full...